To explore the feasibility of performing rapid prenatal diagnoses of FSHD1 using a combination of Bianano optical mapping and linkage-based karyomapping.
| INTRODUCTION
Facioscapulohumeral Muscular Dystrophy (FSHD; MIM 158900; MIM 158901) is a common form of inherited human myopathy, with an estimated prevalence of 1:20,000 1 , presenting typically before age 20, with progressive weakness of the muscles of the face, shoulders and upper arms 2 . FSHD is inherited as an autosomal dominant disease, due to a genetic deletion in chromosomal region 4q35. It can be divided into two types: FSHD1 and FSHD2 according to the underlying genetics. The current consensus is that the causative genetic defect in FSHD is the loss of transcriptional repression of the Double Homeobox Protein 4 (DUX4) gene present in each repeat of the macrosatellite array (D4Z4) at chromosome 4q35 3 .
FSHD1 is more frequent (~95% of cases). The majority of FSHD1 patients (70-90%) inherit the deletion from one parent (50% risk of inheriting), a significant number (10-30%) of cases are due to de novo mutations. FSHD1 is characterized by: 1) variable length deletions of 3.3 Kb (D4Z4) repeated elements at chromosomal region 4q35.
Normally people have 11-100 repeats; but most FSHD patients have 1-10 repeats; 2) disease-linked 4qA allele in 4q35 subtelomere; 3) hypomethylation of D4Z4 repeats. FSHD2 (about 5% of cases) is usually caused by mutations at the SMCHD1 (Structural Maintenance of Chromosomes Hinge Domain 1 gene, on chromosome 18p11.32) or DNMT3B gene which also leads to the hypomethylation of D4Z4 repeats 4 . Both of FSHD1 and FSHD2 cause misexpression of the double homeobox 4 (DUX4) and subsequently the toxic protein ( Figure 1 ). FSHD is not fatal disease, but there is no effective treatment. And it presents with clinical heterogeneity and continual aggravation, so that patients and their families bear a huge psychological burden.
Most families wish to perform prenatal diagnosis. The traditional genetic method of FSHD diagnosis is by pulse field gel electrophoresis (PFGE) and Southern Blot which 5,6 is process-complicated, labor-and time-intensive, needs a large quantity of high quality DNA, and can't ccurately recognize critical length 6, 7 . These deficiencies are tolerable in gene diagnosis but intolerable in prenatal diagnosis, so a simpler and more accurate method would be advantageous. In a recent approach shown by Dai Y et al 8 , the commercial Bionano Saphyr single DNA molecule optical mapping system is well suited for the rapid diagnosis of FSHD1. This method produces ordered genome-wide restriction maps by optical inspection and sizing of restriction fragments from single linearized DNA molecules 9 .
In this study, we explored the new method of Bionano optical mapping combined with Karyomapping as new strategy for prenatal diagnosis.
| MATERIALS AND METHODS
The affected family ( Figure 2A 
What does this study add?
In this study, we explored the approach of combining Bionano optical mapping with Karyomapping as new strategy for prenatal diagnosis for rapid and accurate prenatal diagnosis of family FSHD1. 
| Bionano optical mapping detection

| The pretreatment and comparison of data
| Karyomapping
| DNA sample preparation
Genomic DNA was extracted from the peripheral blood samples and fetal chorionic amniotic fluid samples using a DNA extraction kit (Omega blood/tissue DNA kit, Georgia, United States) according to the manufacturer's instructions.
| Karyomapping and haplotype analysis
The target region haplotypes identified using the Humankaryomap- All of them were located at the 5' end of the D4Z4 repeats 10 . 
| RESULTS
| Bionano optical mapping
| karyomap analysis
The FSHD1 family haplotypes were constructed using the Karyomap SNP-array method. The results of this analysis are shown in Figure 4 . 
| Bionano optical mapping of fetal amniotic fluid cells
The results are shown in Figure 3C and 3D, and indicated that the fetus had one pathogenic chromosome 4 with 4 D4Z4 repeats and the 4qA allele, while its normal chromosome contained 30 D4Z4 repeats, and also the 4qA allele. The fetus' pathogenic sequences were similar to those of its affected father (the proband), indicating that the fetus would likely be positive for FSHD1 disease. The results of Bionano optical mapping using fetal amniotic fluid cells were consistent with the results obtained by Karyomapping linkage-analysis using fetal amniotic fluid cells.
| DISCUSSION
The genetic diagnosis of FSHD1 is very difficult, because of the special DNA structural features involved in the genetics of this disease: Recently, the Bionano optical mapping technique has been used for FSHD1 gene diagnosis 8, 13 . In the present study, we utilized Bionano optical mapping for prenatal diagnosis in a FSHD1 familiy with positive history. We used white blood cells from the proband (the father), proband's mother and fetal amniotic fluid cells. The pathogenic 4q35 region of the 3 family members (fetus, father, grandmother) all had only 4 D4Z4 repeats and the 4qA allele, and the D4Z4 repeats were clearly distinguished from the 10q26 repeats. Southern Blot is still the "gold standard" 6 , but it is not so accurate because it detects the length of all D4Z4 repeats, and not their exact number. Research by Yi et al [8] and Qian et al [13] showed that Bionano optical mapping provided an accurate molecular diagnosis of FSHD, deriving haplotypes consistent with gold standard Southern blotting.
Karyomapping is mostly used in pre-implantation genetic diagnosis (PGD) 15 . However, in the present study, we employed this technique for prenatal diagnosis along with Bionano optical mapping.
Karyomapping can be used to perform linkage analysis for prenatal diagnosis of FSHD1 as an indirect diagnosis, through the detection of SNP loci, to construct family members' haplotypes, and to determining whether a fetus has inherited the family's pathogenic chro- 
